Literature DB >> 6372023

Anaerobes in liver abscess.

J Sabbaj.   

Abstract

Non-spore-forming anaerobic bacteria are recognized as the most numerous and important pathogens in pyogenic liver abscess. These infections are usually polymicrobial. Frequent causes of anaerobic liver abscess are acute and chronic inflammatory bowel disease with or without perforation, malignancy and/or surgery of the gastrointestinal tract or pelvic organs, and biliary tract disease. Many abscesses are still classified as cryptogenic. A thorough understanding of bacterial etiology and the use of refined and accurate localizing and diagnostic techniques facilitate early diagnosis and effective treatment. In addition, the availability of bactericidal antimicrobial agents with extended spectra of activity against anaerobes and their use in selected cases is changing the classic therapeutic approach of antimicrobial therapy and open surgical drainage. Percutaneous aspiration has been used successfully in lieu of open drainage in several cases and antimicrobial treatment without drainage has been successful in others.

Entities:  

Mesh:

Year:  1984        PMID: 6372023     DOI: 10.1093/clinids/6.supplement_1.s152

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

1.  Pyrosequencing reveals the complex polymicrobial nature of invasive pyogenic infections: microbial constituents of empyema, liver abscess, and intracerebral abscess.

Authors:  C D Sibley; D L Church; M G Surette; S E Dowd; M D Parkins
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-28       Impact factor: 3.267

2.  Liver abscess caused by Clostridium bifermentans following blunt abdominal trauma.

Authors:  S Nachman; A Kaul; K I Li; M S Slim; J A San Filippo; K Van Horn
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

3.  Septic embolism in the intensive care unit.

Authors:  Stanislaw P Stawicki; Michael S Firstenberg; Michael R Lyaker; Sarah B Russell; David C Evans; Sergio D Bergese; Thomas J Papadimos
Journal:  Int J Crit Illn Inj Sci       Date:  2013-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.